Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mary Kathryn Duncan"'
Autor:
Mary Kathryn Duncan, Alane Drexler, Marcie J. Hursting, Robert Levine, Jamie M. Walker, John L. Francis
Publikováno v:
The American Journal of Emergency Medicine. 25:279-284
Background Patients with heparin–platelet factor 4 (PF4) antibodies, particularly platelet-activating ones, are at risk for heparin-induced thrombocytopenia if administered heparin. We determined the heparin-PF4 antibody prevalence in emergency dep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ffa22ff0e45680de28a0a3425f9246d
https://doi.org/10.1016/j.ajem.2006.07.015
https://doi.org/10.1016/j.ajem.2006.07.015
Autor:
Ali Amirkhosravi, Alane Drexler, Edward Reyes, Hina Desai, John L. Francis, Mary Kathryn Duncan, Theresa Robson, Mildred Amaya, Kristin Rathmann, Todd Meyer
Publikováno v:
Blood. 108:1051-1051
The laboratory diagnosis of heparin-induced thrombocytopenia (HIT) relies on the demonstration of antibodies to the heparin-platelet factor 4 (H-PF4) complex. Assays are based on the functional ability of H-PF4 antibodies to activate platelets, or de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b8fffa541fcec6d6c66fbef4d6d3529
https://doi.org/10.1182/blood.v108.11.1051.1051
https://doi.org/10.1182/blood.v108.11.1051.1051
Publikováno v:
Blood. 104:2067-2067
Heparin is widely used to treat patients that present with acute coronary syndromes (ACS). A significant, albeit under-recognized complication of heparin therapy is heparin-induced thrombocytopenia (HIT), which is estimated to occur in 1–3% of pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f0d3a0877ecd3a12c18355bebe594ad
https://doi.org/10.1182/blood.v104.11.2067.2067
https://doi.org/10.1182/blood.v104.11.2067.2067